NEW YORK, March 12, 2026, 8:09 PM EDT.
Kenvue Inc slid 1.6% to $17.39 late Thursday, tracking a 2.2% drop in Kimberly-Clark that trimmed the real-time value of its proposed Tylenol-maker takeover. With Kimberly-Clark shares slipping, the mixed offer was pegged at about $17.81 for each Kenvue share—just a shade above Kenvue’s last trade.
Kenvue’s stock isn’t being valued on its own performance right now. Instead, it’s all about the merger math. There’s about a 42-cent difference—what Wall Street calls a merger spread—between Kenvue’s current price and the value of the agreed bid. That gap signals investors still see some risks left: the timing, regulatory hurdles, and ongoing litigation, even after both sets of shareholders gave the deal their approval in January.
As laid out in the SEC filing, Kenvue shareholders will get $3.50 in cash and 0.14625 of a Kimberly-Clark share for every share they hold. But after Kimberly-Clark slipped on Thursday, the value of the stock component fell by about 33 cents.
The drop unfolded alongside a broad selloff. Wall Street closed deep in the red as oil prices charged toward $100 on the Iran war news; the S&P 500 shed 1.52%, the Dow dropped 1.56%. Procter & Gamble and Colgate-Palmolive both gave up roughly 1.8%, while Church & Dwight slipped 0.5%. “Sell first, ask questions later,” Ryan Detrick of Carson Group summed up the tape. Reuters
Kenvue entered the session showing a bit more stability in its operations. The company topped fourth-quarter forecasts on Feb. 17, crediting solid self-care and essential-health demand, and announced plans to trim roughly 3.5% of its global staff ahead of the Kimberly-Clark merger.
Kirk Perry, the chief executive, said at the time that Kenvue closed out 2025 with “stronger top- and bottom-line performance” and kept its attention on finishing the combination. The company added it won’t issue forward guidance as long as the deal is pending. Kenvue Investors
The cloud hasn’t lifted yet. On Feb. 26, a Texas judge shot down Kenvue’s attempt to toss out Texas Attorney General Ken Paxton’s lawsuit over Tylenol warning labels. Reuters noted that Kenvue still faces an appeals court’s pending decision in over 500 private cases tying Tylenol use during pregnancy to autism. Back when the deal was unveiled, TD Cowen’s Robert Moskow flagged that Kimberly-Clark would be inheriting litigation risk that’s tough to pin down.
Kenvue holds a Hold rating from 15 analysts, according to Reuters market data as of Feb. 26. The stock is trading just below the offer value—suggesting investors are still betting the deal wraps up in the second half of 2026, but there’s some hesitation about the final hurdles.
